Streetbeat News

BFRI

Biofrontera Inc.

https://www.biofrontera.us.com

Industry

Drug Manufacturers - Specialty & Generic

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Biofrontera announced the achievement of two milestones related to its Series B-3 Convertible Preferred Stock Warrants, which will lead to $8M in payments to the company upon exercise of these warrants.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 12:55 pm

In Monday's after-market session, several healthcare stocks showed significant movement. Kineta, Moleculin Biotech, and Cue Health were among the top gainers, with Kineta leading at a 24.3% increase. Conversely, BioSig Technologies, Scinai Immunotherapeutics, and Processa Pharma were the top losers, with BioSig Technologies dropping by 16.9%. These movements reflect the volatile nature of healthcare stocks in the market.

Portfolio Pulse from Benzinga Insights

April 08, 2024 | 8:31 pm

Jabil Inc. shares fell over 14% after reporting Q2 results and FY25 guidance below estimates. Other stocks also showed significant movement, with notable gainers including Verb Technology and Better Therapeutics, and losers like C3is Inc. and SELLAS Life Sciences.

Portfolio Pulse from Avi Kapoor

March 15, 2024 | 6:31 pm

Earnings reports for March 15, 2024, include a mix of expected quarterly losses and gains across various sectors. Notable companies like EHang Holdings, NeoGenomics, and Jabil are among those scheduled to report. The forecasts range from losses in sectors like technology and healthcare to gains in consumer goods and services.

Portfolio Pulse from Benzinga Insights

March 15, 2024 | 9:15 am

Biofrontera (NASDAQ:BFRI) is expected to report a Q4 EPS of $-1.19 on March 15, 2024. Previous quarters show a pattern of not meeting EPS estimates, leading to negative stock price reactions. Shares are currently trading at $1.63, down 86.85% over the last year. Investors are looking for positive guidance beyond the earnings beat or miss.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 3:01 pm

In Thursday's after-market session, health care stocks showed significant movement. Ainos (AIMD) led the gainers with a 100% increase, while Biofrontera (BFRI) experienced the largest decline at 15.1%. Other notable movers include Talphera (TLPH) and Macrogenics (MGNX), with their recent Q4 earnings influencing their stock prices.

Portfolio Pulse from Benzinga Insights

March 07, 2024 | 9:31 pm

In Friday's after-market session, several healthcare stocks showed significant movement. Ainos (AIMD) led the gainers with a 54.3% increase, while Healthcare Triangle (HCTI) led the losers with an 8.1% decrease. Other notable movers included Aadi Bioscience (AADI), Taysha Gene Therapies (TSHA), and Biolase (BIOL).

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 9:32 pm

In Wednesday's after-market session, several healthcare stocks experienced significant movements. Virpax Pharmaceuticals, Talphera, Brainstorm Cell, NKGen Biotech, 180 Life Sciences, and ENDRA Life Sciences were among the gainers, with increases ranging from 7.14% to 12.3%. Conversely, Synaptogenix, Portage Biotech, Bright Green, Motus GI Holdings, Fresh2 Group, and Biofrontera were the losers, with their stock prices declining between 6.86% and 19.6%.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 9:31 pm

International Flavors & Fragrances Inc. (IFF) shares fell by 8.4% after reporting mixed Q4 results and cutting its dividend by 50%. Other stocks moved significantly in the session, with notable gainers including Greenbrook TMS Inc. (GBNH), Emergent BioSolutions Inc. (EBS), and Ventyx Biosciences, Inc. (VTYX), among others. Losers included AtlasClear Holdings, Inc. (ATCH), Shineco, Inc. (SISI), and Synchronoss Technologies, Inc. (SNCR), with various reasons such as poor financial results, weak guidance, and regulatory issues.

Portfolio Pulse from Avi Kapoor

February 21, 2024 | 6:50 pm

In Wednesday's pre-market session, several healthcare stocks showed significant movement. Inspire Veterinary, Motus GI Holdings, and Talphera were among the top gainers, with notable increases in their stock prices. Conversely, Avinger, Biofrontera, and Teladoc Health were among the top losers, experiencing significant declines. NeoGenomics and Teladoc Health released their Q4 earnings, impacting their stock prices.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 1:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.